Summary of the technology
We propose a novel compound for the treatment of asthma. We suggest to use this new compound named XIIPHONATE as new lipid-mimetic molecule that inhibits recombinant Autotaxin (ATX), as a potential local, long-term treatment for asthma. This approach is based on the fact that a novel bioactive lipid mediator, Lysophosphatidic acid (LPA), has a pivotal role in the pathogenesis of asthma. It was reported that LPA is synthesized from LPC through the enzymatic activity of ATX. Clinical data show that the levels of ATX protein, and LPA are significantly elevated the in airspaces of patients with asthma. Thus, XIIPHONATE, will inhibit LPA overproduction that leads to the pathologic state. It will therefore present a new therapeutic modality for asthma.
Project ID : 6-2016-4268
Description of the technology
Life Sciences and Biotechnology
Cancer, Asthma, Inhibitor, Autotaxin
Current development stage
Verified in several preclinical models
A new approach to treat metastatic disease has been developed and verified in several preclinical models. This oral treatment, a novel small molecule, acts extracellularly and thereby prevents the metastatic spread. The new molecule has been successfully tested for Asthma models and will be further studied for its efficiency at in-vivo models for cancer.
- The new compounds’ activity is limited to the extracellular compartment, thus there is no intracellular activity (toxicity)
- The activity of the new compound lasts at least 48 h following single oral administration
- The compound has unique clinical potential as cancer and metastasis therapy.
- Molecules of the type of the new compound s are potent inhibitors of extracellular enzymes that support tumor and metastatic growth
The novel compound targets zinc-dependent enzymes in the extracellular milieu involved in tumor dissemination:
- Autotaxin (ATX) which generates lysophosphatidic acid (LPA).
- Carbonic Anhydrases (CA) IX, XII which regulates extracellular pH
- Matrix metalloproteinase (MMP) which regulates ECM degradation
Anti-metastasis therapy is an unmet need. In particular, there is no oral treatment to this clinical problem. We discovered a new approach to treat metastatic disease in that was verified in several preclinical models.